联合检测p53自身抗体与EB病毒VCA-IgA对鼻咽癌的诊断价值

doi:10.3969/j.issn.1004-616x.2015.01.006

Abstract

Abstract:

OBJECTIVE: To evaluate the diagnostic value of serum autoantibodies against p53 in patients with nasopharyngeal carcinoma. METHODS：The study included 242 patients with NPC and 218 normal controls. Serum levels of autoantibodies against p53 and classical Epstein-Barr virus VCA-IgA were measured by Enzyme-linked immunosorbent assay (ELISA). RESULTS：Serum levels of autoantibodies against p53 were significantly higher in NPC than in normal controls (P<0.01). Measurement of autoantibodies against p53 and VCA-IgA demonstrated a sensitivity/specificity of 40.1% (95%CI：33.9%-46.6%)/95.0% (95%CI：90.9%-97.3%) and 47.5% (95%CI：41.1%-54.0%)/95.4% (95%CI：91.5%-97.7%)，respectively. The combination of autoantibodies against p53 and VCA-IgA yielded an enhanced sensitivity of 69.4% (95%CI：63.1%-75.0%) and a similar specificity of 90.8% (95%CI：86.0%-94.2%). Moreover，detection of autoantibodies against p53 could differentiate early stage NPC patients from normal controls. The positive rate of autoantibodies against p53 was not significantly related to age，gender，T stage，N stage or overall stage (P>0.05). CONCLUSION：Autoantibodies against p53 might be used as a potential biomarker supplementary to VCA-IgA for screening and diagnosis of NPC.

Key words: p53, autoantibody, Epstein-Barr virus, VCA-IgA, nasopharyngeal carcinoma, diagnosis

PENG Yuhui，XIE Changle，ZHUANG Shanshan，ZHANG Liqun，XU Yiwei. Combined analysis of autoantibodies against p53 and Epstein-Barr virus VCA-IgA for improved diagnosis of nasopharyngeal carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, doi: 10.3969/j.issn.1004-616x.2015.01.006.

References

[1] Razak AR，Siu LL，Liu FF，et al. Nasopharyngeal carcinoma：the next challenges[J]. Eur J Cancer，2010， 46(11)：1967-1978.

[2] 曹新平，卢泰祥，叶伟军，等. Ⅰ、Ⅱ期鼻咽癌外照射加腔内放疗远期疗效的前瞻性研究[J]. 癌症，2007，26(2)：204-207.

[3] Chen Y，Sun Y，Liang SB，et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China[J]. Cancer，2013，119(12)：2230-2238.

[4] Chan KH，Gu YL，Ng F，et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma[J]. Int J Cancer，2003，105(5)：706-709.

[5] Soussi T. p53 Antibodies in the sera of patients with various types of cancer：a review[J]. Cancer Res，2000，60(7)： 1777-1788.

[6] Chen L，Mao YP，Xie FY，et al. The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China[J]. Radiother Oncol，2012，104(3)：331-337.

[7] Crawford LV，Pim DC，Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer[J]. Int J Cancer，1982，30(4)：403-408.

[8] Xu YW，Peng YH，Chen B，et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma[J]. Am J Gastroenterol，2014，109(1)：36-45.

[9] Zhang J，Xu Z，Yu L，et al. Assessment of the potential diagnostic value of serum p53 antibody for cancer：a meta-analysis[J]. PLoS One，2014，9(6)：e99255.

[10] Roth J，Dittmer D，Rea D，et al. p53 as a target for cancer vaccines：recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge[J]. Proc Natl Acad Sci U S A，1996，93(10)：4781-4786.

[11] Yamamoto S，Chishima T，Adachi S，et al. Serum p53 antibody in breast cancer[J]. Cancer Biomark，2014，14(4)： 203-206.

[12] Pedersen JW，Gentry-Maharaj A，Fourkala EO，et al. Early detection of cancer in the general population：a blinded case-control study of p53 autoantibodies in colorectal cancer[J]. Br J Cancer，2013，108(1)：107-114.

[13] Chang KP，Hao SP，Chang JH，et al. Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes[J]. Clin Cancer Res，2008，14(21)：6979-6987.

[14] Liu Y，Fang Z，Liu L，et al. Detection of Epstein-Barr virus DNA in serum or plasma for nasopharyngeal cancer：a meta-analysis[J]. Genet Test Mol Biomarkers，2011，15(7/8)：495-502.

[1]	GUO Zhaomeng, ZHANG Hua, ZHANG Peng. Mechanisms of Orai1 on invasion and epithelial-mesenchymal transformation in nasopharyngeal carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 420-425.
[2]	HUANG Xiaohua, NIU Yongdong, SHI Ganggang. Inhibitory effects and mechanisms of nuclear receptor FXR activation in cervical cancer cell line CaSki [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 302-306.
[3]	WANG Yaokun, CHEN Juexiao, ZHANG Mingyuan, SHAO Changli, YANG Yu, SHANG Yu. Database analysis of genome variations and targeted drug screening of anaplastic thyroid cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 53-57.
[4]	TAO Yan, LI Lanlan, LU Jianzhong, LIU Shanhui, FU Shengjun, ZHANG Jing. Expression and clinical significance of FOXO3 gene in bladder cancer based on bioinformatics database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 374-379.
[5]	XU Haiming, LIU Keliang, HAO Yanxing, WANG Ling, LIU Zhihong, DE Xiaoming. Usefulness of combined application of biomarkers in early auxiliary diagnosis of silicosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 395-397,401.
[6]	CHEN Qi, ZHONG Qian, YUE Wentao. Inhibition of nasopharyngeal carcinoma proliferation by RBM24 via regulation of HOTAIR [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 275-280.
[7]	DING Wenping, LU Yuanyuan, TONG Wenxia, ZHOU Aibin, KONG Xiang, CHEN Yihong. Induction of apoptosis in HepG2 hepatocellular carcinoma cells by chloroquine via the P38MAPK pathway [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 430-434.
[8]	JIANG Pengtao, HU Zhifang, GAO Xingchun, GUO Na, ZHANG Dian, JIANG Fengliang. Involvement of p53 in regulation of DNA damage-induced cell death in MDA-MB-231 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 349-353.
[9]	HE Huijing, LIU Jincheng, LIU Qianqian, WANG Yun. A variant of Epstein-Barr virusencoded small RNA 2 enhanced resistance to apoptosis by inhibiting the PKR pathway in nasopharyngeal carcinoma cell lines [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 333-338,344.
[10]	XU Yiwei, GUO Hong, GUO Haipeng, PENG Yuhui. Serum level and clinical diagnostic value of DKK1 in adenocarcinoma at the esophago-gastric junction [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(2): 139-142.
[11]	LI Huiying, LI Yang. Effect of RNAi silenced p53 gene on expression of nuclear transcription factor 3 in cervical cancer HeLa cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(1): 46-50.
[12]	LÜ Peng, MAN Qizhong, WANG Yue, ZHUANG Zhengping, WANG Aiping, ZENG Yixin. Effects of protein phosphatase 2A inhibition on radiosensitivity of nasopharyngeal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(4): 262-268.
[13]	CHEN Jiongyu, PENG Lin, HUANG Yiteng, LIN Xueqiong. Involvement of prohibitin during radiation-induced apoptosis in nasopharyngeal carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(3): 200-204.
[14]	JING Shaowu, XU Qing, WANG Jun, YANG Congrong, LI Guangqing, ZHAO Zhen, ZHAO Zhijun, JING Shanghua. Relationship between aberrant expression of E-cadherin and clinicopathological characteristics of nasopharyngeal carcinoma: a Meta-analysis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(2): 97-102,106.
[15]	QU Yanxia, CHEN Guilan, TANG Ying, JIANG Fan, ZUO Liandong, GU Junmei, LI Zhihua. Analysis on screening and prenatal diagnosis of non-deletion α-thalassemia in Guangzhou [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(2): 145-148.

Combined analysis of autoantibodies against p53 and Epstein-Barr virus VCA-IgA for improved diagnosis of nasopharyngeal carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments